Table 7.
Applications of nanoparticle in N2B delivery for treatment of other CNS diseases and pain.
| Drug | Nanocarrier | Lipids | Surfactant/Co-Surfactant | Surface Modification | Size, nm |
Z-Potential, mV |
PDI | EE, % |
DTE, % |
DTP, % |
Ref. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Tapentadol | Chitosan Nanoparticle | - | - | - | 201.2 ± 1.5 | +49.3 ± 1.2 | 0.201 ± 0.01 | 63.49 ± 1.61 | 321 ± 60 | 68.85 ± 0.49 | [263] |
| Baclofen | PLGA Nanoparticle | - | Poloxamer 407 | - | 124.8 | −20.4 | 0.225 | 86.45 ± 1.65 | 183.85 | 45.92 | [264] |
| Teriflunomide | NLC | Compritol 888 ATO/Maisine 35-1/ | Gelucire 44/14/Tween 20 | - | 99.82 ± 1.36 | −22.29 ± 1.8 | 0.35 ± 0.01 | 83.39 ± 1.24 | - | - | [265] |
| Rosmarinic acid | SLN | HSPC | Soya lecithin/Tween 80 | - | 149.2 ± 18.2 | −38.27 | 0.290 ± 0.021 | 61.9 ± 2.2 | - | - | [266] |
| Artemether | NLC | TM/MCT | PF 68 | - | 123.4 ± 3.6 | −34.4 ± 1.2 | - | 91.2 ± 2.5 | 278.16 | 64.02 | [267] |
| Leucine-enkephalin | TMC Nanoparticle | - | - | - | 443 ± 23 | +15 ± 2 | 0.317 ± 0.17 | 78.28 ±3.8 | - | - | [130] |
| Cyclobenzaprine | TC Nanoparticle |
- | SDC | - | 282.9 ± 15.6 | +27.7 ± 1.2 | - | 80.20 ± 3.2 | 2101 | 95.24 | [132] |
| Lamotrigine | PLGA Nanoparticle | - | Poloxamer 407 | - | 184.6 | −18.8 | 0.082 | 84.87 ± 1.2 | 129.81 | 22.96 | [268] |
| Ondansetron | SLN | Glycerol monostearate | Lecithin/Poloxamer 188 | - | 299.67 | −16.5 | 0.296 | 49.82 | - | - | [269] |
Abbreviations: PDI: polydispersity index; EE: Encapsulation efficiency; DTE: Drug targeting efficiency; DTP: Direct transport percentage; HSPC: Hydrogenated soya phosphatidyl choline; MCT: medium chain triglyceride; NLC: nanostructured lipid carrier; PDI: polydispersity index; PF pluronic F; PLGA: poly lactic-co-glycolic acid; SDC: sodium deoxycholate; SLN: solid lipid nanoparticle; TC: thiolated-chitosan; TM: trimyristin; TMC: trimethyl chitosan.